A custom-made mRNA vaccine, intismeran, significantly reduces the risk of melanoma recurrence or death within two years, marking the first positive phase III result for an individualized cancer vaccine.
Personalized mRNA Vaccine Cuts Melanoma Recurrence and Death Risk in Phase III Trial
A custom-made mRNA vaccine, intismeran, significantly reduces the risk of melanoma recurrence or death within two years, marking the first positive phase III result for an individualized cancer vaccine.
COVID-19 vaccine · Wikimedia — licence per file · rights
This item was produced with AI assistance under the editorial responsibility of Haydamax OÜ.
Monitoring item. The full text is not distributed. Extract and source below.
Same event, other desks
Story file →
ru
Вакцина от меланомы снижает риск рецидива на 42%
23.10 06:01